Today announced the initiation of a phase 1 clinical study of ALKS 37.

Preclinical studies show ALKS 37 targets the gastrointestinal system pursuing oral administration, with limited systemic exposure. ALKS 37 is an element of ALKS 36, a combination drug candidate for the treating discomfort without the relative side effects of constipation. Related StoriesDrug that relieves opioid-induced constipation may help some cancer sufferers live longerNew computer-structured modeling can help improve outcomes for infants with neonatal abstinence syndromeEgalet announces launch of OXAYDO Tablets and IMPACT-Rx initiativeAccording to IMS Wellness, over 200 million prescriptions were written for opioids in 2007 in the usa.For the very first time in this study, we’ve demonstrated that IRS-1, an angiogenic proteins, is expressed in the retina and that aganirsen will be able to successfully attenuate neovascularization by inhibiting IRS-1 expression, without influencing normal vascularisation, noted co-lead author Dr. Matthew Lawrence from RxGen Inc., Hamden, CT, USA. Aganirsen blocks pathological neovascularization by inhibiting IRS-1. Clinical research to date have shown that aganirsen has the capacity to safely and efficiently inhibit the development of progressive corneal neovascularization secondary to infectious keratitis or chemical substance burns both of which may lead to corneal graft alternative.